Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Measles is a highly infectious viral disease which can lead to serious complications. In high income regions of the world such as Western Europe, it causes death in at least 1 in 5000 cases, but as many as 1 in 100 will die in the poorest regions of the world.

Worldwide, measles is still a major cause of death, especially among children in resource-poor countries. In 2011, 158,000 people died of measles – an average of 432 every day. However, over the last twenty years vaccination has dramatically reduced the number of deaths from measles. Since 1990 (when measles killed 872,000 people), over one in 5 of all child deaths averted have been due to measles vaccination.

In the short film below, experts talk about measles and its complications, and the importance of the MMR vaccine.

Read more about the symptoms, how it is passed on and how the MMR vaccine protects people on the Vaccine Knowledge Project website.

Similar stories

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

COVID-19 Vaccinology

University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Oxford University breakthrough on global COVID-19 vaccine

COVID-19 Vaccinology

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Oxford coronavirus vaccine produces strong immune response in older adults

COVID-19 Vaccinology

The ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.

SIMON Says…

Vaccinology

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Coronavirus: the road to vaccine roll-out is always bumpy, as 20th-century pandemics show

COVID-19 Vaccinology

Public trust is key to a successful immunisation programme, writes Samantha Vanderslott in a piece for The Conversation.

There is now clear data on Covid-19 and children: it should be safe to reopen English schools

Parents & Carers Vaccinology

In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.